Research & Trials
- Participate in a Clinical Trial
- Brain Bank
- Clinical Studies Explained
Participate in a Huntington's Disease Clinical Trial or Study
Clinical Trial Information
Clinical trial and study information is updated periodically. Trials listed on this page may be closed. To confirm clinical trial or study availability, contact:
Jody Corey-Bloom, M.D., Ph.D.
Phone: 858-249-0568
Email: jcoreybloom@ucsd.edu
More Information
Search for UC San Diego Health Clinical TrialLearn More About UC San Diego Health Clinical Trials
Clinical Trials
Enrolling Now
KINECT-HD
KINECT-HD (Neurocrine) is a randomized, multicenter, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of the orally active VMAT2 inhibitor Valbenazine in Huntington's Disease patients that present with active chorea.
ENROLLING NOW: The purpose of the study is to evaluate the efficacy and safety of Valbenazine compared with placebo in HD subjects.
PROOF-HD
PROOF-HD is a randomized, multicenter, double-blind, placebo controlled, phase III study, conducted by Prilenia Therapeutics, evaluating the efficacy and safety of Pridopidine in patients with early stage HD.
ENROLLING NOW: The purpose of the study is to evaluate the efficacy, safety, biomarker effects, and functional maintenance of Pridopidine compared with placebo in subjects with early stage HD.
Enrollment Closed
Triplet's SHIELD-HD
Triplet's SHIELD-HD study is a observational study that is investigating how Huntington's Disease progresses over time.
ENROLLMENT CLOSED: The purpose of the study is to observe disease progression for patients with varying manifestations of Huntington's Disease. Key findings may be used to help researchers initiate genetic therapies for HD.
ROCHE
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease.
ENROLLMENT CLOSED: The purpose of the study is to evaluate the efficacy, safety, and biomarker effects of RG6042 compared with placebo in subjects with Huntington's disease.
PRECISION-HD2
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of WVE-120102 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362331 (SNP2).
ENROLLMENT CLOSED: The purpose of the study is to evaluate the safety and tolerability of a single dose of WVE-120102 in subjects with early manifest Huntington's disease.
VACCINEX
VACCINEX is a Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503
ENROLLMENT CLOSED: The purpose of this study is to assess the safety and efficacy of monthly IV administration of a single dosage of VX15/2503 in Huntington's disease.
Study Completed
ENROLL-HD
ENROLL-HD: A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease
STUDY COMPLETED
STUDY COMPLETED
OMEROS
OMEROS: Phase 2 Randomized, Double-Blind, Placebo-Controlled, Sequential, Cohort Study to Evaluate Safety and Efficacy of OMS643762 in Subjects with Huntington’s Disease
STUDY COMPLETED
Pride-HD
Pride-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease
STUDY COMPLETED
Reach2HD
Reach2HD: A randomized, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington disease.
STUDY COMPLETED
SIENABIOTECH
SIENABIOTECH: Open-label Food Effect Study With SEN0014196 in Subjects With Huntington’s Disease
STUDY COMPLETED
Observational Trials
Enrolling Now
Enroll-HD
Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
ENROLLING NOW: A longitudinal, observational, multinational study that will integrate two existing Huntington's Disease (HD) registries, REGISTRY in Europe and COHORT in North America and Australia, while also expanding to include sites in Latin America and Asia. With no end date and annual assessments, the goal of Enroll-HD is to build a large and rich database of longitudinal clinical information and biospecimens. This database will serve as a basis for future studies aimed at developing tools and biomarkers for progression and prognosis, identifying clinically relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies.
Enrollment Closed
Experimental Studies
Enrolling Now
UCSD HD – Behavioral Questionnaire
ENROLLING NOW: A single-center observational study designed to assess behavioral changes characteristic of HD, including apathy, depression, irritability, anxiety, disinhibition, difficulty prioritizing and initiating activities. The HD-BQ consists of 30 items with a 3-point rating scale and takes about 5 minutes to complete. The study will be conducted at UCSD.
Plasma and Salivary Biomarkers for HD
ENROLLING NOW: A single-center observational study designed to assess the potential for saliva and plasma to serve as biospecimens for accessible biomarkers in Huntington’s disease. Upon visit, 4 mL of saliva and 2 tsp of blood will be collected and analyzed for huntingtin protein and various biomarkers. Such biomarkers may serve as a utility for symptom onset and, perhaps disease severity. The study will be conducted at UCSD.
Estimating HD Onset Using a Low-Cost Balance Assessment
ENROLLING NOW: A single-center, observational study designed to enhance the estimate of Huntington’s disease onset using a simple and practical body sway assessment device (i.e. BTrackS™). A brief balance assessment will be administered with and without a Paced Auditory Serial Addition Test (PASAT) to subjects with HD, at-risk for HD, and non-HD control subjects. The study will be conducted at UCSD.
Handwriting Movement Abnormalities as an Early Biomarker of Transition to Manifest HD
ENROLLING NOW: A single-center, observational study designed to test whether handwriting movement abnormalities can distinguish individuals at risk for developing HD from normal controls. The MovAlyzeR® software is used to run a brief battery of tasks consisting of five different writing patterns: simple loops, complex loops, rapid overlay circles, Archimedes’ spiral, and the sentence “The sky is blue”. The study will be conducted at UCSD.
Reaction Time in HD Using the Computer Test of Information Processing
ENROLLING NOW: A single-center, observational study designed to identify reaction time deficits that may be associated with individuals diagnosed with HD. A computerized reaction time task will be administered to subjects with diagnosed with HD, at-risk for HD, and non-HD control subjects. The study will be conducted at UCSD.
Study Completed
Prospective Memory Deficits in HD
STUDY COMPLETED: A single-center, observational study designed to identify a fundamental, yet relatively unexamined, memory deficit that may affect the execution of various daily living skills in individuals diagnosed with HD. A paper-and-pencil prospective memory task will be administered to subjects with early manifest HD and non-HD control subjects. Eligible subjects will be between the ages of 35 and 75. Participation will require one visit. The study will be conducted at UCSD. Approximately 40 subjects will be enrolled.
Temporal Order Memory Deficits in HD
STUDY COMPLETED: A single-center, observational study designed to identify a processing deficit that may affect the execution of various daily living skills in individuals diagnosed with HD. A computerized visuospatial temporal order memory task will be administered to subjects with early manifest HD and non-HD control subjects. Eligible subjects will be between the ages of 35 and 75. Participation will require one visit. The study will be conducted at UCSD. Approximately 40 subjects will be enrolled.
Assessment of Basal Ganglia Signaling Pathways Affected in HD
STUDY COMPLETED